嗜铬细胞瘤中骨质疏松与动脉粥样硬化的共存:对其长期管理的新见解
研究比较51例嗜铬细胞瘤患者与51例无功能肾上腺肿瘤患者的影像学表现,发现嗜铬细胞瘤患者椎体骨折患病率更高(37% vs 12%,p=0.005),且椎体骨折与腹主动脉钙化独立相关(OR 1.53,95%CI 1.07-2.46,p=0.003),两者共存比例更高(22% vs 2%,p=0.003)。
要点
- 嗜铬细胞瘤患者椎体骨折患病率37%,高于无功能肾上腺肿瘤患者的12%(p=0.005)。
- 嗜铬细胞瘤患者中,椎体骨折者腹主动脉钙化患病率58%,无椎体骨折者仅6%(p<0.001)。
- 校正年龄和性别后,腹主动脉钙化与椎体骨折相关(OR 1.53,95%CI 1.07-2.46,p=0.003)。
核心结论
- 本研究首次证明嗜铬细胞瘤患者中骨质疏松与动脉粥样硬化频繁共存。
- 嗜铬细胞瘤患者中,骨质疏松的存在可能预测动脉粥样硬化的存在,反之亦然。
- 这些发现对嗜铬细胞瘤及其潜在慢性并发症的长期管理具有意义。
研究设计与样本
- 研究纳入51例嗜铬细胞瘤患者和51例无功能肾上腺肿瘤患者,通过影像学比较椎体骨折和腹主动脉钙化的患病率。
主要发现
- 嗜铬细胞瘤患者中,椎体骨折者腹主动脉钙化患病率为58%,无椎体骨折者为6%(p<0.001)。
- 校正年龄和性别后,嗜铬细胞瘤患者中腹主动脉钙化与椎体骨折相关(OR 1.53,95%CI 1.07-2.46,p=0.003)。
- 儿茶酚胺过量程度与椎体骨折和腹主动脉钙化的存在相关(p=0.007)。
- 嗜铬细胞瘤患者椎体骨折患病率为37%,高于无功能肾上腺肿瘤患者的12%(p=0.005);两组腹主动脉钙化患病率分别为25%和19%(p=0.636),无显著差异。
- 椎体骨折与腹主动脉钙化共存的比例在嗜铬细胞瘤患者中为22%,高于无功能肾上腺肿瘤患者的2%(p=0.003)。
关键数值与推荐
- 嗜铬细胞瘤患者中,腹主动脉钙化与椎体骨折的OR为1.53(95%CI 1.07-2.46,p=0.003)。
- 嗜铬细胞瘤患者椎体骨折患病率37% vs 无功能肾上腺肿瘤患者12%(p=0.005)。
- 嗜铬细胞瘤患者腹主动脉钙化患病率25% vs 无功能肾上腺肿瘤患者19%(p=0.636)。
- 椎体骨折与腹主动脉钙化共存比例:嗜铬细胞瘤患者22% vs 无功能肾上腺肿瘤患者2%(p=0.003)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Osteoporosis and atherosclerosis frequently coexist in patients with pheochromocytoma. The presence of osteoporosis may predict that of atherosclerosis and vice versa in patients with PHEO. These findings have implications for the long-term management of the pheochromocytoma and its potential chronic complications. INTRODUCTION: Pheochromocytoma (PHEO), a catecholamine-producing tumor, is often found incidentally, and it may be present for years before it is diagnosed. However, long-term exposure to catecholamines excess may induce chronic complications, such as osteoporosis and atherosclerosis. We aimed to evaluate concomitant osteoporosis and atherosclerosis in patients with PHEO. METHODS: Fifty-one patients with PHEO and 51 patients with a non-functional adrenal tumor were compared radiographically for the prevalence of vertebral fracture (VF), a typical osteoporotic fracture, and abdominal aortic calcification (AAC). RESULTS: In patients with PHEO, the prevalence of AAC was higher in those with VF (58%) than in those without (6%, p < 0.001). AAC was associated with VF after adjusting for age and sex (odds ratio, 1.53; 95% confidence interval, 1.07-2.46; p = 0.003) in patients with PHEO. The degree of catecholamine excess correlated with the presence of VF and AAC (p = 0.007). The prevalence of VF was higher in patients with PHEO (37%) than those with non-functional AT (12%, p = 0.005), but the prevalence of AAC was comparable between the two groups (25% and 19%, p = 0.636). VF and AAC more frequently coexisted in patients with PHEO (22%) than in those with non-functional AT (2%, p = 0.003). CONCLUSION: This study represents the first demonstration that osteoporosis and atherosclerosis frequently coexist in patients with PHEO. The presence of osteoporosis may predict that of atherosclerosis and vice versa in patients with PHEO. These findings have implications for the long-term management of the PHEO and its potential chronic complications.
引用
- Yokomoto-Umakoshi M, Umakoshi H, Ogata M, et al. Coexistence of osteoporosis and atherosclerosis in pheochromocytoma: new insights into its long-term management. Osteoporos Int. 2020. PMID: 32617610. doi:10.1007/s00198-020-05527-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。